New Hampshire's Recovery Friendly Workplace Initiative Supports Culture Change and Business Impact, Survey Finds
CONCORD, N.H.--(BUSINESS WIRE)--According to a 2024–2025 survey conducted by New Hampshire's Recovery Friendly Workplace (RFW) initiative in partnership with the Behavioral Health Improvement Institute at Keene State College, 91% of responding Recovery Friendly Workplaces (RFWs) reported positive workplace changes over the past year as a result of participating in the initiative.
New Hampshire's Recovery Friendly Workplaces provide a hand up to Granite Staters seeking to better their lives as they recover from substance use disorders
Share
"This round of evaluation was especially important to us in terms of getting a more in-depth sense of how RFW is serving the business community," said Samantha Lewandowski, Senior Director of RFW for Granite United Way. "We are really encouraged by these results, as there are significant indicators of supportive cultures being developed at our RFWs."
The survey also found:
95% of respondents shared that RFW helped them feel better equipped to respond to employee concerns about substance use.
76% had at least one employee disclose a mental health and/or substance use concern.
57% helped at least one employee seek treatment.
52% expressed an increased willingness to hire people in recovery.
Notable improvements in workplace culture, including:
Enhanced support for employees
Increased connections to resources
Expanded training opportunities
Improved trust within the workplace
The most valued RFW resources included staff support, educational materials, and tailored training opportunities.
'New Hampshire's Recovery Friendly Workplaces provide a hand up to Granite Staters seeking to better their lives as they recover from substance use disorders,' said Governor Kelly Ayotte. 'I'm proud to support this important program, and I thank the RFW team and businesses across our state who are helping to create a culture of support for people in recovery.'
"Granite United Way is proud to administer this initiative in partnership with the Governor's Office, and we are pleased to see how these efforts are strengthening the workplace as a pillar of community support," shared Shannon Swett, Chief Impact Officer for Granite United Way.
For more information about the Recovery Friendly Workplace initiative or to get involved, please visit recoveryfriendlyworkplace.com.
About Recovery Friendly Workplace
The New Hampshire Governor's Recovery Friendly Workplace (RFW) initiative was founded in 2018 by Governor Chris Sununu, is administered by Granite United Way, and is a current initiative of Governor Kelly Ayotte. The mission of RFW is to help employers address the impacts of substance use by fostering supportive, recovery-friendly work environments where employees can thrive, in turn, building stronger workplaces and healthier communities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Concentra Announces the Appointment Of Vipin Gopal and Brigid Bonner To Its Board Of Directors
ADDISON, Texas--(BUSINESS WIRE)--Concentra ® Group Holdings Parent, Inc. ('Concentra') (NYSE: CON), today announced the appointment of Vipin Gopal and Brigid Bonner to the Concentra Board of Directors, marking a strategic milestone for the occupational health services company. 'We are pleased to welcome Vipin Gopal and Brigid Bonner to the Concentra Board,' said Bob Ortenzio, Concentra's board chair. 'As Concentra navigates growth and the opportunity to increase shareholder value, expanding the Board with two prominent health care leaders with data, technology, and business transformation expertise will prove to be a mobilizing force for the company.' Vipin Gopal, PhD, brings over 25 years of experience successfully leading data, AI, and digital transformation of Fortune 100 companies. He is a recognized thought leader in leveraging technology to maximize business value, with broad health care industry experience gained through roles across payor, provider, pharmaceutical, and retail pharmacy organizations. Gopal has served as the Chief Data and Analytics Officer at two major companies: Eli Lilly and Company and Walgreens Boots Alliance. In these roles, he was the enterprise executive leader responsible for driving next-generation data and AI strategy and operations across various lines of business. Previously, he was the senior vice president of analytics at Humana and held leadership roles at Cigna, United Technologies Corporation, and Honeywell. Gopal obtained his doctorate from Carnegie Mellon University and from the Indian Institute of Technology (IIT), Bombay, both in engineering, and holds an MBA from the NYU Stern School of Business. 'Concentra analyzes vast amounts of health care data, empowering our clinicians by providing them with valuable insights for superior clinical decision making,' said Keith Newton, Concentra's chief executive officer. 'And, with AI expected to revolutionize numerous aspects of care, Vipin will apply his deep knowledge to help provide guidance to the Concentra organization moving forward.' Brigid Bonner is the president of Bonner Consulting, a firm focused on strategy and digital and personal transformation. She leverages her expertise to help leaders chart their course, whether in pursuit of personal life planning or organizational strategy. Her specialties include strategic planning, business development, digital transformation, consumer experience, and strategic coaching. Bonner has over 35 years of experience as a senior executive traversing nonprofit, for-profit, start-up, and Fortune 100 organizations. Her industry expertise includes retail, technology, e-commerce, and health care. She has held senior leadership roles with CaringBridge, UnitedHealth Group, IBM, Target Corporation, The Schwan Food Company, and Bonner earned her Bachelor of Science degree from Iowa State University, with a double major in journalism/advertising and industrial administration, and her Master of Business Administration degree from Harvard Business School. 'Brigid has made significant contributions to the success of many innovative, high-growth businesses in the health care industry,' continued Newton. 'As the health care landscape continues to become more complex with broad trends in technology innovation at the forefront, Brigid joins the board at a most opportune time, and we welcome her contributions.' Founded in 1979, Concentra has played a significant role in creating the workplace health industry model that exists today. Our national presence enables us to provide access to high-quality care that supports our mission to improve the health of America's workforce. With these two new appointments, the Concentra Board of Directors expands to seven members, composed of outstanding leaders in medicine, finance, and health care organizational management. To learn more, visit About Concentra Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America's workforce, one patient at a time. Our approximately 12,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 50,000 patients each day on average across 45 states at our 627 occupational health centers, 160 onsite health clinics at employer worksites, and Concentra Telemed as of March 31, 2025.
Business Wire
2 hours ago
- Business Wire
Healthpeak Properties Announces Second Quarter 2025 Earnings Release Date and Conference Call Details
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report second quarter 2025 financial results after the close of trading on the New York Stock Exchange on Thursday, July 24, 2025. Healthpeak will host a conference call and webcast on Friday, July 25, 2025, at 8:00 a.m. Mountain Time (10:00 a.m. Eastern Time) to review its financial performance and operating results. The conference call can be accessed in the following ways: Healthpeak's website: Webcast: Joining via webcast is recommended for those who will not be asking questions. Telephone: The participant dial-in number is (800) 715-9871. An archive of the webcast will be available on Healthpeak's website through July 24, 2026, and a telephonic replay can be accessed through August 1, 2025, by dialing (800) 770-2030 and entering conference ID number 95156. ABOUT HEALTHPEAK PROPERTIES Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery. For more information regarding Healthpeak, visit
Business Wire
2 hours ago
- Business Wire
Devonian Health Group Reports Third Quarter 2025 Financial Results
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (' Devonian ' or the ' Company ') (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2025. Management Comments ' The operating cash flows generated by Altius revenues continued to support the development progress of Thykamine™, our lead product candidate, While our distribution agreement for DEXLANSOPRAZOLE has now ended, our liquidity has enabled us to continue creating value by advancing our Thykamine™ development program,' said Dr André Boulet, Chief Executive Officer of the Company. Business Highlights Completed preclinical studies designed to demonstrate new potential applications of Thykamine™ across even more inflammatory diseases, including MASH and fibrosis. Appointment of Dr Andre Boulet as Chief Executive Officer Appointment of Luc Gregoire as Executive Vice-President Strategy Financial Highlights Distribution revenue for the third quarter was $7.36 million driven by DEXLANSOPRAZOLE revenues which launched in early 2024 but has now ended as of April 2025 The Company recorded during the quarter a non-cash impairment loss of $4.84 million against goodwill and intangible assets associated with the expiration of the Dexlansoprazole agreement which represented 95% of revenue in the current fiscal year to date Net loss for the quarter was $4.8 million, or $0.032 per share, entirely attributable to the $4.84 million non-cash impairment loss mentioned above To consult the Interim Consolidated Financial Statements for the three and nine month periods ended April 30, 2025 and 2024, please click on the following link: About Devonian Devonian Health Group is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the ' Exchange ') (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit About Altius Altius is a generic pharmaceutical distribution division with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialization activities required to successfully launch and distribute these medicines in Canada. Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Company's projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine™ might not be granted, and, generally, the above 'About Devonian' and 'About Altius' paragraphs, which essentially describes the Company's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.
